Picture of Viridian Therapeutics logo

VRDN Viridian Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Annual cashflow statement for Viridian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-41.9-111-79.4-130-238
Depreciation
Non-Cash Items3.8876.32319.862.5
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital1.654.431.7216-9.43
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-36.1-29.8-54.6-93.8-184
Capital Expenditures-0.084-0.042-0.338-0.797-0.898
Purchase of Fixed Assets
Other Investing Cash Flow Items28.3-50.4-74-114-93.4
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities28.2-50.5-74.3-115-94.3
Financing Cash Flow Items0.033-1.35-6.95-18.9-7.15
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.07101125322226
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-7.7621.1-3.6113-52.8